Quantcast
Last updated on April 23, 2014 at 20:10 EDT

Latest Drug-eluting stent Stories

2013-10-15 16:26:12

Angioplasty and bypass surgery can lead to similar longterm benefits, finds study led by Saint Luke's Mid America Heart Institute researchers published in Journal of the American Medical Association KANSAS CITY, Mo., Oct. 15, 2013 /PRNewswire-USNewswire/ -- For patients with diabetes and coronary artery disease in more than one artery, treatment with coronary artery bypass graft (CABG) surgery provided slightly better health status and quality of life between six months and two...

2013-10-09 20:22:35

MAJESTIC Trial To Study Self-Expanding DES System Designed To Treat Superficial Femoral Artery (SFA) Lesions NATICK, Mass., Oct. 9, 2013 /PRNewswire/ -- Launching a key clinical trial expected to serve as the foundation for global regulatory approvals, a physician in Auckland, New Zealand has performed the first patient implant of the Boston Scientific Corporation (NYSE: BSX) Innova(TM) Drug-Eluting Stent (DES) System. The MAJESTIC trial -- designed to evaluate the safety and...

2013-10-01 08:31:13

-- Hefei Life Science will fund and manage clinical development and distribution -- DURHAM, N.C., Oct. 1, 2013 /PRNewswire/ -- Micell Technologies, Inc. has entered into an agreement with Hefei Life Science Technology Park Investment and Development Co., Ltd. (Hefei Life Science), for the clinical development, marketing and distribution of the MiStent Sirolimus Eluting Absorbable Polymer Coronary Stent System (MiStent SES(®))( )in the People's Republic of China ("PRC"), including...

2013-09-30 08:29:06

-- TCT 2013 presentation of data planned -- DURHAM, N.C., Sept. 30, 2013 /PRNewswire/ -- Micell Technologies, Inc. today announced that a peer reviewed article discussing imaging and clinical results of the DESSOLVE I trial of its MiStent Sirolimus Eluting Absorbable Polymer Coronary Stent System (MiStent SES(®)) was accepted for publication on the JACC Cardiovascular Interventions website. The paper, "First-in-Human Evaluation of a Bioabsorbable Polymer-Coated Sirolimus-Eluting...

2013-09-24 23:40:13

Barnes-Jewish Hospital is the only hospital in the region implanting a new drug-eluting stent to treat symptomatic blockages of leg arteries caused by peripheral artery disease. St. Louis (PRWEB) September 24, 2013 Although drug-coated stents have been commonly used in coronary procedures, the technology is new to the treatment of peripheral artery disease (PAD). Patrick Geraghty, MD, FACS, Washington University vascular surgeon at Barnes-Jewish Hospital, is the first in the regional area...

2013-09-19 23:21:39

Reportbuyer.com just published a new market research report: MediPoint: Peripheral Vascular Stents for the Lower Extremity - US Analysis and Market Forecasts. London (PRWEB) September 19, 2013 Summary Endovascular therapies such as stenting have been widely adopted to treat peripheral artery disease (PAD) in the lower extremity. Peripheral vascular stents including bare metal, drug-eluting, covered and bioabsorbable stents are associated with improved clinical outcomes compared to balloon...

2013-09-17 23:01:33

ABSORB III nationwide clinical trial evaluating the efficiency and safety of absorb drug-eluting Bioresorbable Vascular Scaffolds (Absorb BVS) for coronary artery disease patients. New York, NY (PRWEB) September 17, 2013 The Mount Sinai Medical Center is participating in the nationwide ABSORB III clinical trial testing the performance and potential clinical benefits of a fully dissolvable and temporary drug eluting stent to open heart artery blockages. The randomized trial aims to compare...

2013-09-12 16:27:47

NATICK, Mass., Sept. 12, 2013 /PRNewswire/ -- In a significant milestone toward obtaining additional key regulatory approvals for the SYNERGY(TM)( )Stent System, Boston Scientific Corporation (NYSE: BSX) has completed enrollment in the EVOLVE II randomized, controlled clinical trial. The EVOLVE II trial is designed to further assess the safety and effectiveness of the SYNERGY Stent System and support U.S. Food and Drug Administration and Japanese regulatory approvals for the...

2013-09-11 23:04:03

Transparency Market Research published new "Global Drug Eluting (DES), Bare Metal (BMS) and Other Coronary Stents Market (2011 – 2016)" market research report to its report store. Browse the report with TOC, visit http://www.transparencymarketresearch.com/coronary-stents-market.html. Albany, New York, USA (PRWEB) September 11, 2013 According to Transparency Market Research “Global Drug Eluting (DES), Bare Metal (BMS) and Other Coronary Stents Market (2011 – 2016)” Global...

2013-09-06 12:25:31

Coating artery-opening stents with a new compound may someday eliminate a common side effect of the treatment, according to preliminary research in the American Heart Association journal Arteriosclerosis, Thrombosis, and Vascular Biology. Stents are tiny mesh tubes that prop open clogged arteries so blood will flow freely to heart muscle, relieving chest pain and reducing the risk of heart attack. But implanting a stent damages the inner lining of the artery, triggering overgrowth of...